Why is New Journey Health Technology Group Co., Ltd. ?
- Poor long term growth as Net Sales has grown by an annual rate of 2.71% and Operating profit at 17.17% over the last 5 years
- High Debt Company with a Debt to Equity ratio (avg) at times
- ROCE(HY) Lowest at 1.1%
- RAW MATERIAL COST(Y) Grown by 14.72% (YoY)
- DEBT-EQUITY RATIO (HY) Highest at 101.72 %
- Over the past year, while the stock has generated a return of -17.80%, its profits have risen by 38.8% ; the PEG ratio of the company is 2.9
- Along with generating -17.80% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
How much should you sell?
- All quantity irrespective of whether you are making profits or losses
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to re-enter? - We will constantly monitor the company and review our call based on new data
Is New Journey Health Technology Group Co., Ltd. for you?
High Risk, Low Return
Quality key factors
Valuation Key Factors 
Technical key factors
Technical Movement
Highest at CNY 407.13 MM
Lowest at 1.1%
Grown by 14.72% (YoY
Highest at 101.72 %
Lowest at 2.55 times
Lowest at CNY 668.21 MM
Lowest at CNY -1.76 MM
Lowest at -0.26 %
Lowest at CNY -37.86 MM
Lowest at CNY -45.82 MM
Lowest at CNY -0.01
Here's what is working for New Journey Health Technology Group Co., Ltd.
Operating Cash Flows (CNY MM)
Here's what is not working for New Journey Health Technology Group Co., Ltd.
Net Sales (CNY MM)
Pre-Tax Profit (CNY MM)
Net Profit (CNY MM)
Net Sales (CNY MM)
Operating Profit (CNY MM)
Operating Profit to Sales
Pre-Tax Profit (CNY MM)
Net Profit (CNY MM)
EPS (CNY)
Debt-Equity Ratio
Debtors Turnover Ratio
Raw Material Cost as a percentage of Sales






